DURHAM – EPI Health, a subsidiary of Durham-based pharmaceutical firm Novan, has landed a licensing deal with Japan-based Sato Pharmaceuticals for a facial treatment.
EPI will receive a $5 million upfront payment and more funding if the product Rhofade (a treatment for rosacea) wins approval in Japan.
“Since 2017, our relationship with Sato has been a valuable component of our strategy and we are pleased to further deepen and expand our partnership with Sato through this license agreement,” said Novan CEO Paula Brown Stafford in a statement. “We are committed to growing our revenue-generating product portfolio and believe the expansion of our commercial initiatives for RHOFADE into Japan represents a promising opportunity.”
